thiamine has been researched along with Diabetic Glomerulosclerosis in 25 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiamine deficiency has been linked to microvascular complications in patients with diabetes mellitus (DM)." | 5.38 | Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria. ( Abd-Alrahman, SH; Al-Attas, OS; Al-Daghri, NM; Alfadda, AA; Sabico, S, 2012) |
| "A 64-year-old male patient with diabetic nephropathy had been treated with maintenance hemodialysis therapy for 4 years, and had developed disturbed consciousness." | 5.33 | Severe thiamine deficiency resulted in Wernicke's encephalopathy in a chronic dialysis patient. ( Iino, Y; Kaneko, T; Katayama, Y; Mii, A; Saito, SK; Takada, D; Tsuzuku, Y; Ueda, K; Utsumi, K, 2006) |
| " Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination." | 4.91 | Vitamin B and its derivatives for diabetic kidney disease. ( Gor, D; Rangoonwala, AN; Raval, AD; Thakker, D; Walia, R, 2015) |
| "Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43)." | 2.77 | Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. ( Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Heeringa, P; Kleefstra, N; Navis, GJ; Schalkwijk, CG; Scheijen, JL, 2012) |
| "Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43)." | 2.75 | A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. ( Achenbach, U; Alkhalaf, A; Bakker, SJ; Bilo, HJ; Gans, RO; Kleefstra, N; Klooster, A; Mijnhout, GS; Navis, GJ; Slingerland, RJ; van Oeveren, W, 2010) |
| "Thiamine is a water-soluble vitamin, rapidly expelled from the body, with no issues of over-dosage or accumulation; unfortunately, it is non-patentable, and neither industry nor independent donors are interested in investing in large-scale randomized controlled clinical trials to investigate its potential in diabetes and its complications." | 1.62 | Thiamine and diabetes: back to the future? ( Beltramo, E; Mazzeo, A; Porta, M, 2021) |
| "Metformin was withheld and signs and symptoms quickly resolved." | 1.48 | Metformin-induced encephalopathy: the role of thiamine. ( Bynevelt, M; Franconi, C; McGarvey, C; Prentice, D, 2018) |
| "Thiamine deficiency was highly prevalent in all groups, whereas low vitamin B₁₂ and elevated methylmalonic acid were rare." | 1.42 | Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. ( Bangert, V; Hostalek, U; Kaiser, RP; Nix, WA; Obeid, R; Schilling, M; Zirwes, R, 2015) |
| "Thiamine deficiency has been linked to microvascular complications in patients with diabetes mellitus (DM)." | 1.38 | Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria. ( Abd-Alrahman, SH; Al-Attas, OS; Al-Daghri, NM; Alfadda, AA; Sabico, S, 2012) |
| "One hundred and fifteen patients with type 2 diabetes with and without microalbuminuria or albuminuria and 39 healthy people were recruited." | 1.38 | Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia--link to renal status, glycemic control and vascular inflammation. ( Adaikalakoteswari, A; Adam, JM; Kariadi, SH; Rabbani, N; Thornalley, PJ; Tjokroprawiro, A; Waspadji, S, 2012) |
| "A 75-year-old man with diabetic nephropathy treated with hemodialysis visited to a medical office because of slight fever, and received intravenous glucose infusion without any vitamins." | 1.36 | [Wernicke encephalopathy in a non-alcoholic patient with diabetic nephropathy under hemodialysis]. ( Kikuchi, S; Mochizuki, H; Moriya, A; Nakatani-Enomoto, S; Sugiura, Y; Ugawa, Y, 2010) |
| "Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats." | 1.35 | Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. ( Balakumar, P; Chakkarwar, VA; Singh, M, 2009) |
| "A 64-year-old male patient with diabetic nephropathy had been treated with maintenance hemodialysis therapy for 4 years, and had developed disturbed consciousness." | 1.33 | Severe thiamine deficiency resulted in Wernicke's encephalopathy in a chronic dialysis patient. ( Iino, Y; Kaneko, T; Katayama, Y; Mii, A; Saito, SK; Takada, D; Tsuzuku, Y; Ueda, K; Utsumi, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yako, H | 1 |
| Niimi, N | 1 |
| Kato, A | 1 |
| Takaku, S | 1 |
| Tatsumi, Y | 1 |
| Nishito, Y | 1 |
| Kato, K | 1 |
| Sango, K | 1 |
| Ghaiad, HR | 1 |
| Ali, SO | 1 |
| Al-Mokaddem, AK | 1 |
| Abdelmonem, M | 1 |
| Beltramo, E | 1 |
| Mazzeo, A | 1 |
| Porta, M | 1 |
| Chalásová, K | 1 |
| Pácal, L | 2 |
| Pleskačová, A | 1 |
| Knopfová, L | 1 |
| Řehořová, J | 2 |
| Tomandlová, M | 2 |
| Tomandl, J | 2 |
| Kaňková, K | 2 |
| McGarvey, C | 1 |
| Franconi, C | 1 |
| Prentice, D | 1 |
| Bynevelt, M | 1 |
| Nix, WA | 1 |
| Zirwes, R | 1 |
| Bangert, V | 1 |
| Kaiser, RP | 1 |
| Schilling, M | 1 |
| Hostalek, U | 1 |
| Obeid, R | 1 |
| Raval, AD | 1 |
| Thakker, D | 1 |
| Rangoonwala, AN | 1 |
| Gor, D | 1 |
| Walia, R | 1 |
| Riaz, S | 2 |
| Schupp, N | 1 |
| Dette, EM | 1 |
| Schmid, U | 1 |
| Bahner, U | 1 |
| Winkler, M | 1 |
| Heidland, A | 1 |
| Stopper, H | 1 |
| Balakumar, P | 1 |
| Chakkarwar, VA | 1 |
| Singh, M | 1 |
| Alkhalaf, A | 3 |
| Kleefstra, N | 3 |
| Groenier, KH | 2 |
| Bakker, SJ | 3 |
| Navis, GJ | 3 |
| Bilo, HJ | 3 |
| Klooster, A | 1 |
| van Oeveren, W | 1 |
| Achenbach, U | 1 |
| Slingerland, RJ | 1 |
| Mijnhout, GS | 1 |
| Gans, RO | 2 |
| Nakatani-Enomoto, S | 1 |
| Moriya, A | 1 |
| Kikuchi, S | 1 |
| Mochizuki, H | 1 |
| Sugiura, Y | 1 |
| Ugawa, Y | 1 |
| Svojanovsky, J | 1 |
| Krusová, D | 1 |
| Stepánková, S | 1 |
| Olsovsky, J | 1 |
| Belobrádková, J | 1 |
| Tanhäuserová, V | 1 |
| Muzík, J | 1 |
| Skinner, V | 1 |
| Srai, SK | 1 |
| Rabbani, N | 3 |
| Thornalley, PJ | 4 |
| Al-Attas, OS | 1 |
| Al-Daghri, NM | 1 |
| Alfadda, AA | 1 |
| Abd-Alrahman, SH | 1 |
| Sabico, S | 1 |
| Adaikalakoteswari, A | 1 |
| Waspadji, S | 1 |
| Tjokroprawiro, A | 1 |
| Kariadi, SH | 1 |
| Adam, JM | 1 |
| Polizzi, FC | 1 |
| Andican, G | 2 |
| Çetin, E | 2 |
| Civelek, S | 2 |
| Yumuk, V | 2 |
| Burçak, G | 2 |
| Heeringa, P | 1 |
| Scheijen, JL | 1 |
| Schalkwijk, CG | 1 |
| Larkin, JR | 1 |
| Zhang, F | 1 |
| Godfrey, L | 1 |
| Molostvov, G | 1 |
| Zehnder, D | 1 |
| Candan Polizzi, F | 1 |
| Babaei-Jadidi, R | 1 |
| Karachalias, N | 1 |
| Ahmed, N | 1 |
| Battah, S | 1 |
| Ueda, K | 1 |
| Takada, D | 1 |
| Mii, A | 1 |
| Tsuzuku, Y | 1 |
| Saito, SK | 1 |
| Kaneko, T | 1 |
| Utsumi, K | 1 |
| Iino, Y | 1 |
| Katayama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Vitamin B Status in Type 2 Diabetes (VITA) Study[NCT03447275] | 174 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy[NCT00565318] | Phase 4 | 86 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thiamine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Vitamin B and its derivatives for diabetic kidney disease.
Topics: Albuminuria; Diabetic Nephropathies; Folic Acid; Humans; Pyridoxamine; Randomized Controlled Trials | 2015 |
Study of Protein Biomarkers of Diabetes Mellitus Type 2 and Therapy with Vitamin B1.
Topics: Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression | 2015 |
Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2011 |
6 trials available for thiamine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients.
Topics: Aged; Antimutagenic Agents; Cell Separation; Cells, Cultured; Diabetic Nephropathies; DNA Damage; Fe | 2008 |
A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
Topics: Adjuvants, Immunologic; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotens | 2010 |
Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2.
Topics: Adult; Aged; Albuminuria; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type | 2011 |
Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; DNA; Female; Glycated Hemogl | 2012 |
Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.
Topics: Aged; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoth | 2012 |
Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2013 |
16 other studies available for thiamine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Role of pyruvate in maintaining cell viability and energy production under high-glucose conditions.
Topics: Adenosine Triphosphate; Animals; Cell Line; Cell Survival; Citric Acid Cycle; Diabetic Nephropathies | 2021 |
Regulation of PKC/TLR-4/NF-kB signaling by sulbutiamine improves diabetic nephropathy in rats.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; | 2023 |
Thiamine and diabetes: back to the future?
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; H | 2021 |
Transketolase Activity but not Thiamine Membrane Transport Change in Response to Hyperglycaemia and Kidney Dysfunction.
Topics: Adult; Aged; Biological Transport; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Erythrocytes; | 2018 |
Metformin-induced encephalopathy: the role of thiamine.
Topics: Adult; Brain Diseases; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Metformin; Thiam | 2018 |
Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Case-Control Studies; Diabetes Mellitus, Ty | 2015 |
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Chelating Agents; Diabetes Mellitu | 2009 |
Thiamine in diabetic nephropathy: a novel treatment modality?
Topics: Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemoglobin; | 2009 |
[Wernicke encephalopathy in a non-alcoholic patient with diabetic nephropathy under hemodialysis].
Topics: Aged; Biomarkers; Diabetic Nephropathies; Humans; Male; Renal Dialysis; Thiamine; Treatment Outcome; | 2010 |
Role of thiamine status and genetic variability in transketolase and other pentose phosphate cycle enzymes in the progression of diabetic nephropathy.
Topics: Adult; Aged; Cross-Sectional Studies; Diabetic Nephropathies; Erythrocytes; Female; Follow-Up Studie | 2011 |
Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Child; Child, Preschool; Cholesterol; Chromatog | 2012 |
Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia--link to renal status, glycemic control and vascular inflammation.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Indonesia; In | 2012 |
Glucose-induced down regulation of thiamine transporters in the kidney proximal tubular epithelium produces thiamine insufficiency in diabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus; Diabetic Nephropathies; Down-Regulation; Epithelium; Gl | 2012 |
Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.
Topics: Albuminuria; Animals; Chelating Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dos | 2003 |
Severe thiamine deficiency resulted in Wernicke's encephalopathy in a chronic dialysis patient.
Topics: Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Ag | 2006 |
Benfotiamine. Monograph.
Topics: Alcoholic Neuropathy; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; | 2006 |